Stereochemistry | RACEMIC |
Molecular Formula | C20H26N2O2 |
Molecular Weight | 326.4326 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(C1CCCCC1)N2CC3N(CCCC4=C3C=CC=C4)C(=O)C2
InChI
InChIKey=LGUDKOQUWIHXOV-UHFFFAOYSA-N
InChI=1S/C20H26N2O2/c23-19-14-21(20(24)16-8-2-1-3-9-16)13-18-17-11-5-4-7-15(17)10-6-12-22(18)19/h4-5,7,11,16,18H,1-3,6,8-10,12-14H2
Molecular Formula | C20H26N2O2 |
Molecular Weight | 326.4326 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Epsiprantel is a veterinary drug which is used as an antiparasitic agent. Epsiprantel in tablets (Cestex) is indicated for the removal of tapeworms in the cat (Dipylidium caninumand Taenia taeniaeformis) and dog (Dipylidium caninum and Taenia pisiformis). Epsiprantel acts directly on the tapeworm. Since it is minimally absorbed following oral administration, epsiprantel remains at the site of action within the gastrointestinal tract. Due to digestive process, tapeworm fragments or proglottids may not be readily visible in the stool. Epsiprantel is not a cholinesterase inhibitor. During the course of clinical field studies, Cestex was administered concurrently with diethylcarbamazine citrate (dogs only), anti-inflammatory agents, insecticides, and nematocides with no drug incompatibilities noted. The mechanism of action of epsiprantel appears to be similar to that of praziquantel, a drug that disrupts the regulation of calcium and other cations. Tetanic muscle contraction and paralysis occurs in the parasite, and the tegument becomes vacuolized
Approval Year
PubMed
Patents
Sample Use Guides
veterinary use:
cats: 1.25 mg/lb of body weight
dogs: 2.5 mg/lb of body weight
Route of Administration:
Oral